Characterization of the GRK2 binding site of Goq*

Peter W. Day‡, John J. G. Tesmer§, Rachel Sterne-Marr#, Leslie C. Freeman#, Jeffrey L. Benovic‡, and Philip B. Wedegaertner‡,§

‡Department of Microbiology and Immunology, Kimmel Cancer Center, Thomas Jefferson University, 233 S. 10th St., Philadelphia, PA 19107, Department of Chemistry and Biochemistry, Institute for Cellular and Molecular Biology, $The University of Texas at Austin, TX 78712-0165, #Biology Department, Siena College, 123 Morrell Science Center, 515 Loudon Rd., Loudonville, NY 12211

SUMMARY

Heterotrimeric guanine nucleotide-binding proteins (G proteins) transmit signals from membrane bound G protein-coupled receptors (GPCRs) to intracellular effector proteins. The Goq subfamily of Ga subunits couples GPCR activation to the enzymatic activity of phospholipase C-β (PLC-β). Regulators of G protein signaling (RGS) proteins bind to activated Ga subunits, including Goq, and regulate Ga signaling by acting as GTPase activating proteins (GAPs), increasing the rate of the intrinsic GTPase activity, or by acting as effector antagonists for Ga subunits. GPCR kinases (GRKs) phosphorylate agonist-bound receptors in the first step of receptor desensitization. The amino-termini of all GRKs contain an RGS homology (RH) domain (Siderovski et al., Curr. Bio., 1996) and binding of the GRK2 RH domain to Goq attenuates PLC-β activity (Carman et al., J. Biol. Chem. 1999). The RH domain of GRK2 interacts with Goq through a novel Ga binding surface termed the “C” site (Sterne-Marr et al., J. Biol. Chem. 2003). Here, molecular modeling of the Goq-GRK2 complex and site-directed mutagenesis of Goq were used to identify residues in Goq that interact with GRK2. The model identifies Pro185 in Switch I of Goq as being at the crux of the interface, and mutation of this residue to lysine disrupts Goq binding to the GRK2-RH domain. Switch III also appears to play a role in GRK2 binding because the mutations Goq-V240A, Goq-D243A, both residues within switch III, and Goq-Q152A, a residue that structurally supports switch III, are defective in binding GRK2. Furthermore, GRK2-mediated inhibition of Goq-Q152A-R183C-stimulated inositol phosphate release is reduced in comparison to Goq-R183C. Interestingly, the model also predicts that residues in the helical domain of Goq interact with GRK2. In fact, the mutants Goq-K77A, Goq-L78D, Goq-Q81A and Goq-R92A have reduced binding to the GRK2-RH domain. Finally, while the mutant Goq-T187K has greatly reduced binding to RGS2 and RGS4 it has little to no effect on binding to GRK2. Thus the RH domain A and C sites for Goq interaction rely on contacts with distinct regions and different switch I residues in Goq.

*Corresponding address: §Philip Wedegaertner, Department of Microbiology and Immunology, Kimmel Cancer Center, Thomas Jefferson University, 233 S. 10th St., 839 BLSB, Philadelphia, PA 19107, Tel: 215-503-3137, Fax: 215-503-2117, E-mail: P_Wedegaertner@mail.jci.tju.edu.

†This work was supported by a fellowship from the American Heart Association Pennsylvania-Delaware Affiliate to P.W.D., American Heart Association Scientist Development Grant 0235273N and a Research Corporation Cottrell Scholar grant to J.J.G.T., National Science Foundation Grants MCB9728179 and MCB0315888 to R.S.M., National Institute of Health Grant GM44944 to J.L.B. and National Institute of Health Grant GM62884 to P.B.W.

The abbreviations are: RH, RGS homology; GPCR, G protein-coupled receptor; PLC-β, phospholipase C-β; GRK, GPCR kinase; GAP, GTPase activating protein; AlF4⁻, aluminum fluoride; RGS, regulator of G protein signaling; GST, glutathione-S-transferase; WT, wild type; DMEM, Dulbecco’s modified Eagle’s medium; GDP, guanosine diphosphate; GTP, guanosine triphosphate.
INTRODUCTION

G protein coupled receptors (GPCRs) are heptahelical integral membrane proteins responsible for the transmission of extracellular signals, such as light, neurotransmitters and hormones, to intracellular signaling pathways. Agonist-bound GPCRs directly interact with heterotrimeric (αβγ) G proteins and catalyze nucleotide exchange on Gα subunits (1). Several mechanisms are in place to ensure the appropriate level of response to an agonist. Receptors become desensitized to agonist stimulation upon phosphorylation by GPCR kinases (GRKs) and subsequent binding of arrestins (2–5). The Gα subunit has intrinsic GTPase activity that returns the G protein to the inactive GDP bound state, promoting reassociation with Gβγ (6).

A third mechanism, which accounts for the rapid desensitization observed in cellular signaling systems such as phototransduction in the eye (7), is attributed to GTPase activating proteins (GAPs), that bind Gα subunits and accelerate the GTPase reaction. GAPs for Gα subunits include effector molecules, such as phospholipase C-β, and regulators of G protein signaling (RGS) proteins (8,9). There are over 30 RGS proteins identified, all of which contain an approximately 130 residue domain called the RGS homology (RH) domain (10,11). RGS proteins act as GAPs by binding to Gα and stabilizing the transition state of GTP hydrolysis (11). The crystal structures of the RH domains from RGS4, RGS9, axin, GRK2, p115RhoGEF and PDZRhoGEF have been determined (11–16). A typical RH domain consists of nine helices organized into a bundle subdomain of helices α4-α7 and a terminal subdomain of helices α1-α3 and α8-α9 (11). The RH domains of RGS proteins contact Gα subunits with a discontinuous surface composed of loops between helices 3/4, 5/6 and 7/8, that has been defined as the A site (17). In contrast, the RH domain of axin, which is not known to bind Gα subunits, binds the adenomatous polyposis coli protein (APC) at a cleft formed between the terminal and bundle subdomains (13). This has been defined as the B site (17).

The RH domain of GRK2 is responsible for specifically binding to active forms of Gαq, Gα11 and Gα14, but not Gαi, Gα12/13 or Gα16 (18–21). The structure of full length GRK2 indicates that its RH domain assumes a fold similar to other RGS proteins with the addition of two α helices contributed by residues 513–547, which follow its protein kinase domain in the primary sequence (14). Previously, we have shown that the binding site for Gαq on the RH domain of GRK2 is distinct from both the RH domain A and B sites (22), and consists primarily of the solvent-exposed surface of the α5 helix. This site is now referred to as the C site (22).

The residues on Gαq required for association with the C site of the GRK2 RH domain are not known. Interestingly, a G188S mutation in Gαq has no effect on the GRK2-Gαq interaction (22), even though this mutation prevents the interaction of Gαq with other RGS proteins (23, 24), suggesting that the Gαq residues critical for interaction with GRK2 are different from those used to bind RGS proteins. However the activation-dependent association of Gαq with GRK2 requires that at least part of the interface involves the switch regions of Gαq (18). In support of this, GRK2 binds chimeric proteins that contain the GTPase domain of Gαq and the helical domain of Gα16, the only Gαq family member that does not interact with the RH domain of GRK2, but not reciprocal chimeras, in an activation dependent manner (19).

In this study we use a molecular modeling approach to identify residues on Gαq that may interact with GRK2. Site-directed mutagenesis followed by GST-pulldown and cellular inositol phosphate assays indicate that contact sites for GRK2 on Gαq include the Switch I and III regions as well as residues in the helical domain of Gαq. Some of these residues are distinct from those that are important for interactions with RGS2 and RGS4. In addition, our previous mutational studies of the GRK2 C site were based upon a homology model of the GRK2 RH domain (22). Because the structure of full-length GRK2 indicates that the α5 helix, the major
point of $\text{Ga}_q$ contact, is significantly longer than modeled (14), we have further refined the C site based on the $\text{Ga}_q$-RH model and the $\text{Ga}_q$ mutagenesis studies described herein.

### EXPERIMENTAL PROCEDURES

#### Materials

HEK-293 cells were from American Type Culture Collection (CRL- 1573). FuGENE 6 transfection reagent was from Roche Molecular Biochemicals. Super Signal West Pico ECL reagents were from Pierce. $\text{Myo-[3]}^\text{H}$ Inositol was obtained from Perkin Elmer Life Sciences. Cell culture media were from Mediatech Cellgro. GRK2 mouse monoclonal antibody was from Upstate Biotechnology. HRP-conjugated antimouse secondary antibody was from Promega. Ultima Flo AF and Ultima Gold scintillation cocktails were from Packard Chemical. All other chemicals and reagents were from Sigma Chemical Co. and Fisher Scientific.

#### Expression Plasmids and Mutagenesis

pcDNA3-$\text{Ga}_q$-R183C ($\text{Ga}_q$-RC) with an internal EE epitope tag was provided by Dr. C. Berlot. EE tagged $\text{Ga}_i$ and $\text{Ga}_q$-Q209L ($\text{Ga}_q$-QL) have been described previously (19). All $\text{Ga}_i$, $\text{Ga}_q$ QL and $\text{Ga}_q$ RC point mutants were created in the background of EE tagged protein using the sequential PCR method (25). The GST-RGS4 expression plasmid was provided by Dr. R. Neubig and pcDNA3-RGS2 was provided by Dr. D. Siderovski. GST-RGS2 was created by using PCR to engineer a 5’ BamH1 site and a 3’ XhoI site onto RGS2 and then subcloning the RGS2 fragment into the BamH1 and XhoI sites of pGEX-5X1. GRK2 constructs have been described previously (18,22). GRK2 mutants were prepared by sequential PCR or by QuikChange Mutagenesis (Stratagene).

#### Cell Culture and Transfection

HEK-293 cells were maintained in Dulbecco’s modified Eagle’s medium plus 10% fetal bovine serum and 100 units/ml penicillin/streptomycin at 37 °C in 5% CO$_2$. Cells in 6 well plates were transfected with 1 µg of DNA and 3 µl of FuGENE, while 3 µg of DNA and 9 µl of FuGENE were used for the transfection of cells in 6 cm dishes.

#### Molecular Modeling

$\text{Ga}_q$ was homology modeled with the SWISS-MODEL server (26) using as a template the structure of $\text{Ga}_i$ (49% sequence identity) in complex with RGS4 (11), which represents the most complete atomic model of an activated $\text{Ga}$ subunit. The model was subsequently verified by ERRAT (27). As expected, the regions of the model evaluated as most unreliable (over the 95% confidence level) are the effector binding loops of $\text{Ga}_q$, which vary greatly among the four $\text{Ga}$ subfamilies. However, the three switch regions of the G protein represent the most likely binding site for GRK2 given its requirement for activated $\text{Ga}_q$ (18). The three switch regions of the model are distant from the effector loops, include some of the most highly conserved residues among $\text{Ga}$ subunits, and are found in essentially the same conformation in all crystal structures that involve an activated $\text{Ga}$ subunit. Evaluation by ERRAT also suggested that these regions were modeled reliably.

To model the GRK2-$\text{Ga}_q$ complex, automated docking programs were tested, but not used because they generally fail to accurately model changes, such as those of side chains, upon complex formation (28,29). We instead imposed several strict constraints based on experimental data to manually dock $\text{Ga}_q$ with GRK2. The resulting model of their complex at the very least should predict which regions of $\text{Ga}_q$ could be responsible for both complex formation and specificity. The first constraint was to limit the GRK2- interaction surface of $\text{Ga}_q$ to its three switch regions and to the $\alphaA$ helix and the $\alphaB$-$\alphaC$ loop in the helical domain.
This constraint derives from the facts that the formation of the GRK2-Gαq complex is dependent on the active conformation of the G protein, and therefore presumably the conformation of its switch regions (18), and that the adjacent αA helix and αB-αC loop have also been shown to contribute to the binding of RH domains in other Ga subunits (12,30). The second constraint was to limit the Gαq interaction surface of GRK2 to solvent exposed residues on the α5 and α6 helices of its RH domain, which were previously identified to be important for complex formation with Gαq (22). The third constraint was to fix the relative orientation of Gαq and GRK2 to the plane of a common cell membrane, as each of their orientations with respect to a cellular membrane is relatively well known from prior crystal structures and electrostatic calculations. The orientation of Gαq with respect to the plane of the plasma membrane, defined by the GRK2-Gβγ structure (14), was fixed by docking it against the Gβγ subunits present in the GRK2-Gβγ complex in a manner similar to Gαi in the Gαi1Gβ1γ2 structure (31). Gαq was then translated and rotated along the plane of the membrane until its GRK2-interaction surface was adjacent to the Gαq-interaction surface of GRK2. The model was manually adjusted to optimize the packing of residues at the protein interface, and then minimized using simulated annealing in CNS(32) to relieve any bad contacts between side chains. Harmonic restraints were imposed on the Cα positions during refinement to keep the backbone relatively fixed (0.28 Å root mean squared deviation between initial and final coordinates of Gαq). The modeled interface buries 2100 Å² of surface area, which is on par with or larger than those observed in crystal structures of other RH domain-Gα complexes (e.g. 1,800 Å² in the RGS9-Gαt/i complex(12)). The final model of the complex was verified by the program PROCHECK(33), ERRAT, and VERIFY3D, which indicated that the residues involved in the interface were consistent with a reasonably packed and complementary structure.

Inositol Phosphate Production Assay

HEK-293 cells were transfected with 0.1 μg of EE GαqRC or EE Gαq RC mutant constructs, 0.2 μg of myc-His tagged Gβ1, 0.1 μg of Gγ2, the indicated amounts of GRK2-K220R or RGS2 and pcDNA3 up to a total of 1 μg DNA. Twenty-four hours after transfection, cells were replated on 4 wells of a 24- well plate and 3 wells were labeled for 16 h with 2 μCi/ml [3H]-inositol. Inositol phosphate production was determined as previously described (22). Results are the average of at least three experiments done in triplicate and represented as Percent Control. Control is the level of inositol phosphate produced in the absence of cotransfected GRK2-K220R or RGS2. Graphing and statistical analysis, as described in Figure legends, was performed using GraphPad Prism.

The fourth well of replated transfected cells was used to monitor whether the coexpression of GRK2 or RGS2 had any effect on the expression of Ga subunits. Cells were lysed with 50 μl of SDS sample buffer, vigorously homogenized and boiled for 5 minutes. 20 μl of the sample was then subjected to 12 % SDS-PAGE and transferred to PVDF. The PVDF was then probed with 2 μg/ml of EE monoclonal antibody followed by horseradish peroxidase-conjugated secondary antibody (1:10,000 dilution). Pierce SuperSignal West Pico reagents were used to visualize immunoblots. Blots from assays with GRK2-K220R were stripped with a 50 mM glycine buffer, pH 2.0, and reprobed with a GRK2 specific monoclonal antibody followed by horseradish peroxidase-conjugated secondary antibody (1:10,000 dilution) to determine the effect of transfecting increasing amounts of GRK2-K220R cDNA on GRK2 expression.

Purification of GST fusion proteins

GST-GRK2-(45–178), GST-RGS2 or GSTRGS4 were expressed in BL-21 cells and purified using glutathione Sepharose 4B beads (from Amersham Life Sciences) essentially as described in Sterne-Marr et al (22) for GST-GRK2-(45–178). The glutathione Sepharose bound GST-
GRK2-(45–178), GSTRGS2 or GST-RGS4 is washed three times in lysis buffer to remove any glycerol before being added to the lysates.

**GST-GRK2-(45–178), GST-RGS2 and GST-RGS4 Interaction Assays**

HEK-293 cells were transfected in 6 cm dishes with 2.0 μg of Gαq or mutant Gαq cDNA, 0.2 μg of myc-His tagged Gβ1, 0.1 μg of Gγ2, and pcDNA3 up to a total of 3.0 μg of DNA. 24 h after transfection cells were washed with cold PBS and lysed with 0.3 ml of lysis buffer (20 mM Tris-HCl, pH 7.4, 1 mM EDTA, 1 mM dithiothreitol, 100 mM NaCl, 5 mM MgCl2, 0.7 % Triton X-100, 1 mM phenylmethylsulfonyl fluoride, and 5 μg/ml leupeptin and aprotinin). After 1 h of lysis at 4°C, cells were centrifuged for 3 min at full speed in a microcentrifuge. For Gαq-RC and Gαq-QL assays, 200 μl of the supernatant was removed to a new tube and incubated with 8 μg of GST-GRK2-(45–178), GSTRG2 or GST-RGS4, all pre-bound to glutathione Sepharose beads, for 1-2 h at 4°C. The remaining supernatant, denoted “L” for lysates, was saved for subsequent immunoblot analysis alongside pull down samples. After incubation of the lysates with the GSTGRK2-(45–178), GST-RGS2 or GST-RGS4 bound beads, the samples are pelleted at low speed in a microcentrifuge for 3 min and the beads are washed 3 times with lysis buffer. Proteins were then eluted from beads in 50 μl of SDS sample buffer and boiled for 5 minutes.

For GST pull-down assays carried out in the absence or presence of AlF₄⁻, 250 μl of the Gαq-containing supernatant (described above) was removed and split equally into two tubes. To one of the tubes AlCl₃ (25 μM), NaF (5 mM) and MgCl2 (1 mM) were added. GST-GRK2-(45–178), GST-RGS2 or GST-RGS4 (8 μg) bound beads were then added to each tube and incubated for 4–5 h at 4 °C. The remaining supernatant, denoted “L” for lysate, was saved for subsequent immunoblot analysis alongside samples. After incubation of the lysates with the GST-GRK2-(45–178), GST-RGS2 or GST-RGS4 bound beads, the samples are pelleted at low speed in a microcentrifuge for 3 min and the beads are washed 3 times with lysis buffer. Proteins were then eluted from beads in 50 μl of SDS sample buffer and boiled for 5 minutes.

In all cases, 20 μl of each pull-down sample was subjected to 12 % SDS-PAGE and transferred to PVDF, which was probed with 2 μg/ml EE monoclonal antibody followed by horseradish peroxidase-conjugated secondary antibody (1:10,000 dilution). A portion of the initial lysate that represents 4% of the protein present in the lysates was also analyzed on immunoblots alongside GST pull-down samples and indicated by “L” in figures. Pierce SuperSignal West Pico reagents were used to visualize immunoblots. For graphical representation of pull-down assays images of western blots were acquired using a Kodak DC-40 digital camera and the net intensity of each band was calculated using Kodak Digital Science 1D Image Analysis Software. The percent of the mutant Gαq that was pulled-down by the GST-fusion protein was calculated and compared to the control, which is the percent of Gαq that interacted with the GST-fusion protein and displayed as percent control + S.D. Graphing and statistical analysis, as described in Figure legends, was performed using GraphPad Prism.

**Pull-down Assays with GRK2 RH Domain Mutants**

Mutants of the GRK2 RH domain were assayed as GST-GRK2-(45–178) fusions using bovine brain extract as a source of WT Gαq as described (22). To allow comparison of severely defective Gαq-binding mutants, a more sensitive assay was developed by using 20 μg/ml fusion protein and 500 μg/ml bovine brain extract protein in the pull-down assays.
RESULTS

**Molecular modeling of the G \( \alpha_q \)-GRK2 interface**

The binding surface for \( \alpha_q \) has been localized primarily to the \( \alpha_5 \) helix of the GRK2 RH domain and is distinct from the protein-binding surfaces used by other RH domains (11,13,22). Accordingly, this interaction surface has been termed the C site, following the nomenclature proposed by Zhong and Neubig (17). GRK2 only interacts with activated \( \alpha_q \) (18) suggesting the involvement of at least one \( \alpha_q \) switch region in the interaction. However, the C site of the RH domain may bind residues on \( \alpha_q \) that are distinct from those that interact with RGS proteins such as RGS2 and RGS4. We have already shown that the RGS-resistant Switch I mutant, \( \alpha_q \)-G188S, retains association with GRK2 (22).

In order to predict which \( \alpha_q \) residues could interact with the RH domain of GRK2, a homology model of \( \alpha_q \) was manually docked with the RH domain from the GRK2-G\( \beta \gamma \) crystal structure (14) by imposing several specific constraints required by prior biochemical and structural analyses (see methods). The docking model predicts that the long \( \alpha_5 \) helix of the GRK2 RH domain docks into the cleft formed between the helical domain and the Ras-like domain of GRK2 and engages primarily switch I and III of the Ras-like domain (Figure 1 A). This binding mode would be substantially different from those observed for the complexes of \( \alpha_q \) and GRK2 with RGS4 (11) and RGS9 (12), respectively (Figure 1 B), although in each case the switch regions of \( \alpha_q \) provide the primary interaction site. In particular, the model predicts that Pro\( ^{185} \) of \( \alpha_q \) is at the crux of the interface with its side chain packing against Asp\( ^{110} \), Met\( ^{114} \) and Leu\( ^{118} \) of GRK2 (Figure 1 C–D). Indeed, both Asp\( ^{110} \) and Met\( ^{114} \) have previously been shown to be important for the interaction of GRK2 with \( \alpha_q \) (22). Residues within the \( \alpha A \) helix of \( \alpha_q \) were also predicted to be in close proximity to the GRK2 RH domain, and could explain why residues such as Val\( ^{137} \) of GRK2, which is quite distant from Asp\( ^{110} \), Met\( ^{114} \) and Leu\( ^{118} \) of GRK2, has an effect on \( \alpha_q \) binding when mutated to alanine. Therefore, residues in both the switch I and III regions and adjacent regions of the helical domain of \( \alpha_q \) were targeted for mutagenesis.

**Identification of G \( \alpha_q \) switch residues that interact with the RH domain of GRK2**

To test the effects of point mutations in the switch I and III regions of \( \alpha_q \), they were transiently over-expressed in HEK-293 cells, and GST-GRK2-(45–178) was then used to pull-down mutant \( \alpha_q \) in lysates from the transfected cells. Each point mutant was made in the background of an otherwise wild-type (non-activated) \( \alpha_q \) and a constitutively active \( \alpha_q \)-Q209L (\( \alpha_q \)-QL). Selected mutants were also generated in the constitutively active \( \alpha_q \)-R183C (\( \alpha_q \)-RC) background and assessed their ability to bind when mutated to alanine. Therefore, residues in both the switch I and III regions and adjacent regions of the helical domain of \( \alpha_q \), which binds G\( \beta \)GDP and occupies the space normally filled by the \( \gamma \) phosphate of GTP. This causes the \( \alpha_q \) subunit to assume a conformation that is thought to mimic the transition state of GTP hydrolysis (34). In contrast, \( \alpha_q \)-QL and \( \alpha_q \)-RC are constitutively active because Glu\( ^{209} \) and Arg\( ^{185} \) are involved in the hydrolysis of the \( \gamma \) phosphate of GTP and their mutation to leucine and cysteine, respectively, greatly decreases the rate of this reaction (34). Initially, binding of the point mutants to GST-GRK2-(45–178) was examined in the AlF\( _4^- \) and \( \alpha_q \)-QL backgrounds. However, we also wanted to examine the effects of the mutations on the ability of GRK2 to inhibit the \( \alpha_q \)-mediated formation of inositol phosphate in cells. Unfortunately, the cotransfection of GRK2-K220R, a kinase deficient mutant of GRK2 (35), caused a marked decrease in the expression of several mutants, particularly K77P, Q152A, P185K, and T187K (data not shown). Previously, we had observed that relatively small amounts of co-transfected GRK2 were able to inhibit inositol phosphate production stimulated by constitutively active \( \alpha_q \)-RC (data not shown). We therefore generated several of the mutants, K77A, Q81A, R92A, Q152A, P185K and T187K, in the \( \alpha_q \)-RC background and assessed their ability to bind.
GRK2. The effect of each mutation on binding to the RH domain of GRK2 was tested, and the results are summarized in Table 1 and described below.

Our model of the GRK2-Ga\textsubscript{q} interaction predicts that Pro\textsubscript{185} is buried within the interface, and therefore will represent a critical specificity determinant. As expected, mutation of Pro\textsubscript{185} to lysine, the corresponding residue in Ga\textsubscript{q}, has a profound negative effect on GRK2 binding (Figure 2 A, B and C). Binding of P185K-QL and P185K-RC (Figure 2 B and C) to the GRK2 RH domain is completely attenuated while binding of P185K in the presence of AlF\textsubscript{4}\textsuperscript{-} is less than 20 % of wild type (Figure 2 A). The mutation of Pro\textsubscript{185}, located in Switch I between the helical domain and the GTPase domain of Ga\textsubscript{q}, does appear to decrease the expression of Ga\textsubscript{q} by approximately 40% (data not shown). However, as will be discussed later, this mutant retains its ability to bind to RGS proteins when activated by AlF\textsubscript{4}\textsuperscript{-}. Therefore, by mutating Ga\textsubscript{q} Pro\textsubscript{185} we disrupt GRK2 binding, as predicted by the model of their complex.

Two additional residues in the Switch I region of Ga\textsubscript{q}, Val\textsubscript{184} and Thr\textsubscript{187}, were also targeted by site-directed mutagenesis. Mutation of Val\textsubscript{184} to aspartic acid is predicted to lessen favorable contacts with Leu\textsubscript{118} of GRK2. The V184D mutant has a modest effect (< 80 % of control) on AlF\textsubscript{4} activated Ga\textsubscript{q} binding to GRK2, but this effect is lost in the Ga\textsubscript{q}-QL background.

Similarly, mutation of Thr\textsubscript{187} to lysine, the corresponding residue in Ga\textsubscript{12/13}, was also predicted to destabilize the GRK2-Ga\textsubscript{q} interface, perhaps by creating unfavorable contacts with the side chains of Lys\textsubscript{115} and Thr\textsubscript{111} of GRK2. However, GRK2 binding to Ga\textsubscript{q} is unaffected by the T187K mutation, regardless of whether it is in the context of Ga\textsubscript{q}-GDP-AlF\textsubscript{4}\textsuperscript{-}, Ga\textsubscript{q}-RC or Ga\textsubscript{q}-QL (Figure 2 A, B and C). Substitution of residues at these positions may be permitted because they exist at the periphery of the interface and thus are partially solvent-exposed in the model. They could thereby accommodate longer side chains.

The model also predicts that the GRK2 RH domain interacts with the backbone of the Switch III residue Val\textsubscript{240} and that there is a potential salt-bridge between Asp\textsubscript{243} of Ga\textsubscript{q} and Lys\textsubscript{139} of GRK2. The Ga\textsubscript{q}-V240A and D243A mutants reduce or eliminate, respectively, AlF\textsubscript{4} activated dependent binding to GRK2 (Table 1). However, both V240A-QL and D243A-QL interact with GRK2 to the same extent as Ga\textsubscript{q}-QL. This suggests that Switch III is more critical for binding in AlF\textsubscript{4} activated Ga\textsubscript{q} than the QL and RC conformations of the enzyme. The structural basis for these differences is not clear, but may be due to subtle conformational changes in the three switches when bound to either GTP or a transition state complex.

Gln\textsubscript{152} is a highly conserved alpha-helical domain residue whose side-chain makes specific hydrogen bonds within the Ras-like domain of Ga subunits, principally with the backbone of Switch III and with a conserved arginine residue that likewise supports Switch III. Because Gln\textsubscript{152} is changed to histidine in Ga\textsubscript{16}, which does not bind GRK2, and because of its proximity to the modeled RH domain, it was also targeted by site-directed mutagenesis.

Q152A-GDP-AlF\textsubscript{4}\textsuperscript{-}, Ga\textsubscript{q}-Q152A-QL and the Q152A-RC have reduced binding to the GRK2 RH domain (Table 1 and Figure 2 A and C). These results with the Q152A, V240A and D243A mutants confirm a role for Switch III in binding GRK2.

**Identification of Ga\textsubscript{q} helical domain residues that interact with the RH domain of GRK2**

Several residues within the helical domain of Ga\textsubscript{q} are likewise predicted to be involved in the interaction with GRK2 (Figure 1). Leu\textsubscript{78} is predicted to interact with GRK2 Leu\textsubscript{118} and the L78D mutant had a slight effect (< 80 % of control) on the AlF\textsubscript{4} activated dependent binding to the GRK2 RH domain (Table 1). Two residues in the \textalpha\textsubscript{1} helix of Ga\textsubscript{q}, Lys\textsubscript{77} and Gln\textsubscript{81}, are expected to interact with the carboxyl terminus of the GRK2 \textalpha\textsubscript{5} helix. The Q81A mutant of Ga\textsubscript{q} has reduced binding to the GRK2 RH in the presence of AlF\textsubscript{4} (Table 1 and Figure 2 A). However, Q81A-QL and Q81A-RC (Table 1 and Figure 2 B and 2 C) retain the ability to bind to the GRK2 RH domain. Replacement of Lys\textsubscript{77} with a proline, the analogous Ga\textsubscript{16} residue,
disrupts AlF₄⁻-dependent binding to GRK2 and binding to GRK2 in the Gaq-QL background (Table 1). In contrast, the K77A mutant only has an effect on binding to GRK2 in the Gaq-QL background (Table 1 and Figure 2 A, B and C). These data support a role for the α-helical domain of Gaq in dictating the specificity and the affinity of the GRK2-Gaq interaction.

There are additional residues in the helical domain that are in close proximity to the GRK2 RH domain in the model but that are not conserved in Ga16. The V118A mutation has no effect on GRK2 binding (Table 1). Mutation of Arg⁹², whose aliphatic side chain is predicted to interact with Val¹³⁷ of GRK2, to alanine does not have an effect on AlF₄⁻-dependent binding or binding to Gaq-RC (Table 1 and Figure 2 A and C); however, reduced binding to GRK2 is seen with R92A-QL (Table 1 and Figure 2 B). In addition to the interactions between the aliphatic portion of the Gaq Arg⁹² side-chain and GRK2 Val¹³⁷, our model predicts that its guanidino group forms a salt-bridge with GRK2 Glu¹³⁰. To test this idea, E130A was introduced into GST-GRK2-(45–178). Similar to another GRK2-α6 mutant V137A, E130A shows a modest deficiency in its ability to bind Gaq/11 in a GST-pull-down assay (data not shown).

**Gaq-Q152A-RC is less sensitive than Gaq-RC to GRK2-mediated inhibition of inositol phosphate production**

We then tested the interaction of GRK2 with Gaq-RC mutants in intact cells. We have previously used co-transfection of Gβγ to stabilize the expression of Gα subunits in the presence of RGS proteins (19). In addition, very low amounts of GRK2-K220R, 5 ng of cDNA, are able to inhibit signaling from Gaq-RC (Table 1). The ability of GRK2-K220R to inhibit Gaq-RC signaling is not affected by the co-expression of Gβγ (data not shown). These conditions allowed us to detect differences in the sensitivity of the point mutants to GRK2 inhibition. Unfortunately, even under these conditions, the expression of the P185K-RC mutant was inversely proportional to the amount of GRK2-K220R transfected (data not shown). Therefore it was not included in these experiments. Even so, the expressed P185K-RC mutant, other than Gaq-P185K, that consistently inhibited the interaction with the RH domain of GRK2 in pull-down experiments is Gaq-Q152A (Table 1 and Figure 2). Q152A-RC also showed resistance to GRK2-K220R inhibition of inositol phosphate production (Figure 3 A). Although the differences in the inhibition of Gaq-RC versus Q152A-RC signaling by GRK2-K220R are small, the effects are reproducible. For example, the transfection of 10 ng of GRK2-K220R led to 25% inhibition of the inositol phosphate stimulated by Gaq-RC, while the same amount of GRK2-K220R did not inhibit Q152A-RC (Figure 3 A). The difference between Gaq-RC and Q152A-RC is less pronounced at higher levels of GRK2-K220R expression, suggesting that this mutant lowers the affinity of but does not totally disrupt the interaction between GRK2 and Gaq (Figure 3 A). This would agree with GST-GRK2 pull-down data that shows a marked decrease in binding to Q152A in the presence of AlF₄⁻ and the Q209L mutation and a smaller decrease in binding to Q152A-RC (Table 1 and Figure 2 A, B and C).

Two of the remaining Gaq mutants tested for inhibition of inositol phosphate production by GRK2 showed only minor defects in GRK2 interaction. Although the Q81A mutant binds to the RH domain of GRK2 in both the QL and RC form (Figure 2 B and C), in the presence of AlF₄⁻ the binding of Q81A is reduced (Table 1 and Figure 2 A). In the inositol phosphate assays with Gaq-Q81A-RC and Gaq-T187K-RC there are small differences in comparison to R183C in the ability of low levels of GRK2 to inhibit signaling (data not shown). However at higher concentrations of GRK2-K220R, Gaq-Q81A-RC and Gaq-T187K-RC are inhibited to a level that is similar to Gaq-RC (data not shown). The R92A-RC mutant is inhibited in a manner that is essentially identical to R183C (data not shown). Importantly, Figure 3 B shows that expression of GRK2-K220R, even at a high level, does not decrease the expression of

*J Biol Chem.* Author manuscript; available in PMC 2006 April 6.
Gaq-RC or the GaqQ152A-RC mutant, indicating that the observed differences in inositol phosphate production are due to differences in binding of GRK2 to Gaq-RC relative to GaqQ152A-RC, and not to differences in expression levels. In general, the data from the inositol phosphate assays are consistent with the pull-down assays with the RH domain of GRK2.

The A sites of RGS2 and RGS4 bind different surfaces of Gaq than the C site of GRK2

We have previously shown that the binding surface for Gaq on the GRK2 RH domain is distinct from that of RGS4, and in this set of experiments we wanted to determine the effect of the mutations made in Gaq on binding to RGS2 and RGS4 (22). There is little or no difference in the ability of RGS2 versus RGS4 to bind each of the Gaq mutants (Table 1), and Figure 4 presents GST pull-down data with RGS2.

Mutation of residues in the Switch I region of Gaq interfere with binding to RGS2 and RGS4. The mutation that has the most profound effect on binding to GRK2, P185K, also does not bind to RGS2 and RGS4 in the context of the RC mutation (Table 1 and Figure 4 C). However P185K activated by AlF4− does bind to RGS4 and RGS2 (Table 1 and Figure 4 A). Finally, the conserved Thr residue (position 187 in Gaq and 182 in Gai), which is completely buried in the Gaq-RGS4 interaction, is essential for binding to RGS2 and RGS4 (11). Substitution of T187 with a lysine drastically reduces binding to RGS2 and RGS4 in all active forms (Table 1 and Figure 4 A, B and C) but has no affect on binding to GRK2 (Table 1 and Figure 2). In addition, we have previously shown that the RGS resistant mutant GaqG188S binds to GRK2 (22). Therefore, there are substantial differences between the surface of Gaq bound by the A site of typical RGS proteins and the C site of the GRK2 RH domain, as predicted by their modeled interactions with Gaq (Figure 1 A–B).

Additionally, there are differences in the binding of RGS2 and RGS4 to AlF4−-activated versus constitutively active RC and QL forms of a few of the helical domain mutants (Table 1 and Figure 4). For example, the mutant Q81A-RC has decreased binding to both RGS proteins as does Q81A activated by AlF4− (Table 1 and Figure 4 A and C); however, GaqQL and the GaqQ81A-QL mutant bind to RGS2 to a similar level (Figure 4 B). Also, the AlF4− activated Q152A and GaqQ152A-QL show decreased binding to RGS2 and RGS4, but Q152A-RC binds RGS2 and RGS4 equally as well as wild-type Gaq-RC does (Table 1 and Figure 4 A, B and C).

Q81A-RC and T187K-RC have reduced sensitivity to RGS2 mediated inhibition of inositol phosphate production

We next wanted to examine the ability of RGS2 and RGS4 to inhibit each of the Gaq point mutants in the RC form. These assays were performed in a manner similar to the inositol phosphate assays with GRK2. The Gβγ subunits were expressed in every sample and increasing amounts of RGS2 were cotransfected with each mutant. We were not able to assess the ability of RGS4 to inhibit the Gaq mutants because transfection of several different RGS4 constructs decreased the expression of Gaq or mutants of Gaq (data not shown). The P185K-RC mutant was not included in these experiments because, like GRK2-K220R, co-expression of RGS2 decreased its expression (data not shown).

Inositol phosphate assays performed to determine the sensitivity of the Gaq point mutants to inhibition by RGS2 agree with the data from the GST-RGS2 pull-down experiments. The two mutants that have very little effect on the binding of RGS2 to Gaq R92A and Q152A, are also susceptible to RGS2 mediated inhibition of inositol phosphate production (Figure 5 A). In contrast, low amounts of transfected RGS2 DNA do not decrease the inositol phosphate production stimulated by Q81A-RC (Figure 5 A). At the highest amount of RGS2 transfected, 20 ng, Q81A-RC stimulated inositol phosphate production is decreased by about 25%.
similar levels of RGS2 decrease R183C stimulated inositol phosphate production by 43% (Figure 5 A). This agrees with the pull-down data in Figure 5 and suggests that this residue is involved in the Gq-RGS2 interaction. Finally, T182 in Gq, which corresponds to T187 in Gaq, is found at the center of the Gq-RGS4 interface and therefore mutation at this position in Gaq should disrupt any interaction with RGS4 and RGS2. Figure 4 shows that very little T187K-RC is pulled-down with GST-RGS2. Figure 5 A also shows that signaling by T187K-RC is not inhibited by co-expression of RGS2. Figure 3 shows that this mutation has no effect on the ability of GRK2-K220R to inhibit Gq signaling, once again highlighting the difference between GRK2 and RGS2 binding sites on Gq. As with GRK2, coexpression of RGS2 does not decrease the expression levels of Gq-RC or any of the mutants (Figure 5 B).

**GRK2 L118A does not interact with Gq**

While our previous GRK2 mutagenesis studies were driven by an axin/GAIP-based homology model of the GRK2 RH domain (22), the crystal structure and the docking model (Figure 1) used in this study to predict Gq residues involved in the interface with GRK2 also identified additional GRK2 residues that could be involved in the interface with Gq. Specifically, the new model predicts that Leu118 of GRK2 is important for the central interaction with Pro185 of Gq. To test this hypothesis, the L118A mutation was introduced into the GST-GRK2-RH domain (residues 45–178), and GST pull-down assays were used to assess the ability of the mutant to bind to Gq/11 from bovine brain extracts in the presence of AlF4−. L118A was markedly impaired in its ability to bind Gq/11, affirming the importance of the solvent-exposed Leu118 in the Gq interaction (Figure 6). The Gq-binding deficiency of L118A is comparable to that of previously identified mutants R106A, D110A and E116A, which also showed severe impairment in Gq/11 binding (22). To compare the L118A mutation to previously identified mutants, the pull-down assay was modified so as to increase its sensitivity. Some binding (except with the R106A/D110A double mutant) can be detected under these conditions allowing the mutants to be ranked based on their decreasing ability to bind Gq/11: R106A > L118A > D110A > R106A/D110A (data not shown). Two additional amino acids in the extended α5 helix of GRK2 were also examined; however, neither T111A nor C120A have any effect on the ability of GST-GRK2-(45–178) to bind Gq/11 (Figure 6).

**DISCUSSION**

Here, Gq-binding residues of GRK2 identified in a previous study (22) and the crystal structure of GRK2 were both used to construct a model of the Gq-GRK2 interaction interface. This model was used to identify Gq residues and additional GRK2 residues that could be involved in the interface (14). While we believe the resulting model is globally correct, there is no way short of determining the crystal structure of the complex to know if it is accurate in detail, especially given that no high-resolution atomic model of Gq currently exists. Therefore, while the manually docked model described here is consistent with the existing biochemical data, it should not be regarded as more than a conceptual tool to help predict regions of Gq that are responsible for binding and specificity.

Our results demonstrate that of the Gq residues tested, Pro185 is the most critical for the Gq-GRK2 interaction (Figure 2), although mutation of other residues within Switch I, III and the helical domain were also found to influence complex formation. Moreover, we show that mutation of Gq residues differentially affect interaction with GRK2 and the canonical RGS proteins, RGS2 and RGS4. Specifically, the T187K mutation significantly reduces binding to and inhibition of signaling by RGS2, but does not affect the GRK2-Gq interaction (compare Figures 2 and 3 to Figures 4 and 5). These results are consistent with the Gq-GRK2 interface being distinct, but overlapping, with that of Ga-RGS proteins (Figure 1 A–B).
Several lines of evidence are consistent with the proposal that the RH domain of GRK2 interacts with the switch regions of G\(\alpha_q\). First, the activation-dependent nature of the interaction between the GRK2 RH domain and G\(\alpha_q\) strongly suggests that the switch regions of G\(\alpha_q\) are involved. Secondly, in a study using G\(\alpha_q\)-G\(\alpha_{16}\) chimeras, we have shown that GRK2 binds to a chimeric G\(\alpha\) protein containing the switch regions of G\(\alpha_q\) but not a chimeric protein containing the switch regions of G\(\alpha_{16}\), a member of the G\(\alpha_q\) family that does not interact with GRK2 (19). Thirdly, modeling G\(\alpha_q\) onto the RH domain of GRK2 predicts that Pro\(^{185}\) of G\(\alpha_q\) makes significant contacts with several residues in GRK2, such as Asp\(^{110}\) and Met\(^{114}\), previously identified as being important for the interaction (22). The fact that Pro\(^{185}\) resides at the crux of the interface would also explain why GRK2 selectively interacts with G\(\alpha_q\) rather than G\(\alpha\), where the corresponding residue is a lysine. Consistent with this idea, the G\(\alpha_q\)-P185K mutant does not bind to GRK2 when activated by AlF\(^{-}\), but it does bind to RGS4 and RGS2 (Table 1 and Figures 2 and 4). P185K-RC not only fails to bind GRK2 but also does not bind RGS2 or RGS4 (Figures 2 and 4). Apparently, in the context of G\(\alpha_q\) with the RC mutation, P185K cannot be tolerated. A previous report suggested that Pro\(^{185}\) and Ile\(^{190}\) of G\(\alpha_q\) contribute to the higher affinity of RGS2 for G\(\alpha_q\), versus G\(\alpha\), by affecting the position of Thr\(^{187}\) relative to the RGS binding pocket (36). If this is true, then it is possible that the combined effects of R183C and P185K change the conformation of Switch I so that it is incompatible with GRK2, RGS2 and RGS4 binding.

The G\(\alpha_q\) residues that mediate critical interactions with the A site of RGS proteins are distinct from those that interact with the C site of GRK2. In the model of the G\(\alpha_q\)-GRK2 complex, Thr\(^{187}\) is close enough to the interface that mutation to lysine could potentially disrupt the interaction. However, mutation of this residue does not affect the G\(\alpha_q\)-GRK2 interaction and therefore does not represent a critical contact site. In contrast, the T187K mutation has a profound effect on the interaction of both RGS2 and RGS4 with G\(\alpha_q\) (Figures 4). In addition, RGS2 does not inhibit signaling from the constitutively active, G\(\alpha_q\)-T187K-RC, form of this mutant (Figure 5). As mentioned previously, the position of Thr\(^{187}\) in G\(\alpha_q\) relative to the binding pocket of RGS2 may determine in part the selectivity of the RGS2-G\(\alpha_q\) interaction (36).

Further differences between G\(\alpha_q\) binding to GRK2 and RGS2 or RGS4 can be seen by mutation of residues in the helical domain of G\(\alpha_q\). One such mutation, Q152A, located in a loop between the a\(\delta\) and a\(\epsilon\) helices, disrupted binding to the RH domain of GRK2 and inhibition by full-length GRK2 in cellular inositol phosphate assays (Figures 2 and 3). The G\(\alpha_q\)-Q152A-RC mutant interacted with both RGS2 and RGS4 in pull-down assays and its stimulation of PLC-\(\beta\) was inhibited by RGS2 (Figures 4 and 5), indicating that the Q152A mutation selectively disrupts the interaction of G\(\alpha_q\) with GRK2. We also identified a mutation in the helical domain of G\(\alpha_q\), Q81A, that has unique effects on RH domain binding specificity. The binding of GST-RGS4, GST-RGS2 and GST-GRK2- (45–178) to AlF\(^{-}\)-activated-Q81A is reduced (Table 1 and Figures 2 and 4). In contrast G\(\alpha_q\)-Q81A-RC, displays decreased interaction with RGS2 and RGS4 but exhibits no defect in its interaction with GRK2 (Figures 2 and 4). Relative to G\(\alpha_q\)-RC, RGS2 inhibition of G\(\alpha_q\)-Q81A-RC stimulated inositol phosphate production is decreased (Figure 5), while GRK2 inhibits both G\(\alpha_q\)-RC and G\(\alpha_q\)-Q81A-RC-stimulated inositol phosphate production to similar levels (data not shown). The finding that the Q81A mutation disrupts the interaction of G\(\alpha_q\) with RGS2 and RGS4 is novel. Additionally, this glutamine is conserved only among the G\(\alpha_q\) family and therefore may be a residue in the helical domain of G\(\alpha\) that could contribute to the targeting of RGS proteins to specific G\(\alpha\) subunits.

Mutation of other residues in the helical domain of G\(\alpha_q\) decreased the interaction with GRK2. Both the K77A and R92A mutations in G\(\alpha_q\) decreased binding to GRK2 in the context of G\(\alpha_q\)-QL (Figure 2B). These results likewise suggest that the RH domain of GRK2 interacts with the alpha helical domain of G\(\alpha_q\). There is evidence from other studies that the helical

\(J\) Biol Chem. Author manuscript; available in PMC 2006 April 6.
domain imparts some of the Gα selectivity upon interactions with RH domains. Skiba et al. used Gαq/Gai chimeras to show that the specificity of RGS9 for Gαi resides in the helical region (37). A second study used RGS2/RGS4 chimeras and point mutants to identify residues in RGS2 that confer Gαq selectivity (36). The RGS2 residues identified in this study would interact with residues in the αA helix in the helical domain of Gαq and would be repelled by analogous residues in Gai (36). In combination with our results, such studies demonstrate that the helical domain of Gα subunits, in particular αA, plays a critical role in the specificity of RH domain-Gα subunit interactions.

Results from several experiments in this study revealed differences in the ability of Gαq to interact with GRK2, depending upon whether the Gα subunit is activated by AlF4−, the R183C mutation or the Q209L mutation. For example, the Q81A mutation disrupts interaction with the RH domain of GRK2 when Gαq is activated by AlF4− but has no effect in the presence of the activating RC and QL mutations (Figure 2). In contrast, GαqK77A-QL and GαqR92A-QL display greatly decreased interaction with the RH domain of GRK2, but GαqK77A-RC, GαqR92A-RC, and AlF4−-activated GαqK77A and GαqR92A efficiently interact with the RH domain of GRK2 (Figure 2). In the cocrystal structure of RGS4 and Gai, Asn128 of RGS4 projects into the active site of Gai and contacts the catalytic residue Gln204 (11). Our model predicts that Gln209 in Gαq could also make direct contact with the RH domain of GRK2, by forming hydrogen bonds with the side chain of Asp110 in GRK2. However, in order to do so it would have to adopt a different, more extended conformation than that observed for the analogous Gai Gln204 residue in the Gai-RGS4 complex (11). While this extended conformation would be predicted to inhibit GTPase activity, such a conformation of Gαq may be appropriate for binding to GRK2, which exhibits little or no GAP activity (18). The constitutively active RC and QL forms of several Gα subunits have been used extensively and somewhat interchangeably to investigate Gα subunit signaling; however, our results suggest that there are functional differences between these constitutively active mutants that may warrant further investigation.

In conclusion, we have used molecular modeling and mutation studies to identify residues that are important for the interaction between the RH domain of GRK2 and Gαq. This data confirms the unique characteristics of the interaction between Gαq and the C site of the GRK2 RH domain and also identifies new residues in the helical domain of Gα that selectively disrupt the interaction between Gαq and RGS2 or RGS4 but not GRK2. The crystal structure of GRK2 and Gβγ in complex allows for a model in which GRK2 is simultaneously interacting with agonist bound receptor, Gβγ and Gαq (14). It would also be interesting to investigate the possibility that Gαq plays a role in directing the Gβγ-recruited GRK2 to specific, activated Gαq coupled receptors.

References

1. Bourne HR. Curr Opin Cell Biol 1997;9:134–142. [PubMed: 9069253]
2. Krupnick JG, Benovic JL. Annu Rev Pharmacol Toxicol 1998;38:289–319. [PubMed: 9597157]
3. Hausdorff WP, Caron MG, Lefkowitz RJ. FASEB J 1990;4:2881–2889. [PubMed: 2165947]
4. Goodman OB Jr, Krupnick JG, Santini F, Gurevich VV, Penn RB, Gagnon AW, Keen JH, Benovic JL. Nature 1996;383:447–450. [PubMed: 8837779]
5. Ferguson SS, Downey WE 3rd, Colapietro AM, Barak LS, Menard L, Caron MG. Science 1996;271:363–366. [PubMed: 8553074]
6. Gilman AG. Ann Rev Biochem 1987;56:615–649. [PubMed: 3113327]
7. Watson N, Linder ME, Druey KM, Kehrl JH, Blumer KJ. Nature 1996;383:172–175. [PubMed: 8774882]
8. Berstein G, Blank JL, Jhon DY, Exton JH, Rhee SG, Ross EM. Cell 1992;70:411–418. [PubMed: 1322796]
9. Ross EM, Wilkie TM. Annu Rev Biochem 2000;69:795–827. [PubMed: 10966476]
10. Hollinger S, Hepler JR. Pharmacol Rev 2002;54:527–559. [PubMed: 12223533]
11. Tesmer JJ, Berman DM, Gilman AG, Sprang SR. Cell 1997;89:251–261. [PubMed: 9108480]
12. Slep KC, Kercher MA, He W, Cowan CW, Wensel TG, Sigler PB. Nature 2001;409:1071–1077. [PubMed: 11234020]
13. Spink KE, Polakis P, Weis WI. EMBO J 2000;19:2270–2279. [PubMed: 10811618]
14. Lodowski DT, Pitcher JA, Capel WD, Lefkowitz RJ, Tesmer JJ. Science 2003;300:1256–1262. [PubMed: 12764189]
15. Chen Z, Wells CD, Sternweis PC, Sprang SR. Nat Struct Biol 2001;8:805–809. [PubMed: 11524686]
16. Longenecker KL, Lewis ME, Chikumi H, Gutkind JS, Derewenda ZS. Structure (Camb) 2001;9:559–569. [PubMed: 11470431]
17. Zhong H, Neubig RR. J Pharmacol Exp Ther 2001;297:837–845. [PubMed: 11356902]
18. Carman CV, Parent JL, Day PW, Pronin AN, Sternweis PM, Wedegaertner PB, Gilman AG, Benovic JL, Kozasa T. J Biol Chem 1999;274:34483–34492. [PubMed: 10567430]
19. Day PW, Carman CV, Sterne-Marr R, Benovic JL, Wedegaertner PB. Biochem 2003;42:9176–9184. [PubMed: 12885252]
20. Usui H, Nishiyama M, Moroi K, Shibasaki T, Zhou J, Ishida J, Fukamizu A, Haga T, Sekiya S, Kimura S. Int J Mol Med 2000;5:335–340. [PubMed: 10719047]
21. Sallese M, Mariggeo S, D’Urbano E, Iacovelli L, De Blasi A. Mol Pharmacol 2000;57:826–831. [PubMed: 10727532]
22. Sterne-Marr R, Tesmer JJ, Day PW, Stracquatanio RP, Cilente JA, O’Connor KE, Pronin AN, Benovic JL, Wedegaertner PB. J Biol Chem 2003;278:6050–6058. [PubMed: 12427730]
23. DiBello PR, Garrison TR, Apanovitch DM, Hoffman G, Shuey DJ, Mason K, Cockett MI, Dohlman HG. J Biol Chem 1998;273:5780–5784. [PubMed: 9488712]
24. Lan KL, Sarvazyan NA, Taussig R, Mackenzie RG, DiBello PR, Dohlman HG, Neubig RR. J Biol Chem 1998;273:12794–12797. [PubMed: 9582306]
25. Ausubel, F. M., Brent, R. E., Kingston, R. E., Moore, D. D., Seidman, J. G., Smith, J. A., and Struhl, K. (1992) Short Protocols in Molecular Biology, second Ed., John Wiley & Sons, New York
26. Schwede T, Kopp J, Guex N, Peitsch MC. Nucleic Acids Res 2003;31:3381–3385. [PubMed: 12824332]
27. Colovos C, Yeates TO. Protein Sci 1993;2:1511–1519. [PubMed: 8401235]
28. Vajda S, Camacho CJ. Trends Biotechnol 2004;22:110–116. [PubMed: 15036860]
29. Wodak SJ, Mendez R. Curr Opin Struct Biol 2004;14:242–249. [PubMed: 15093840]
30. Skiba NP, Yang CS, Huang T, Bae H, Hamm HE. J Biol Chem 1999;274:8770–8778. [PubMed: 10085118]
31. Wall MA, Coleman DE, Lee E, Iniguez-Lluhi JA, Posner BA, Gilman AG, Sprang SR. Cell 1995;83:1047–1058. [PubMed: 8521505]
32. Brunger AT, Adams PD, Clore GM, DeLano WL, Gros P, Grosse-Kunstleve RW, Jiang JS, Kuszewski J, Nilges M, Pannu NS, Read RJ, Rice LM, Simonson T, Warren GL. Acta Crystallogr D Biol Crystallogr 1998;54 (Pt 5):905–921. [PubMed: 9757107]
33. Laskowski RA, MacArthur MW, Moss DS, Thornton JM. J Appl Crystallogr 1993;26:283–291.
34. Coleman DE, Berghuis AM, Lee E, Linder ME, Gilman AG, Sprang SR. Science 1994;265:1405–1412. [PubMed: 8073283]
35. Kong G, Penn R, Benovic JL. J Biol Chem 1994;269:13084–13087. [PubMed: 8175732]
36. Heximer SP, Srinivasa SP, Bernstein LS, Bernard JL, Linder ME, Hepler JR, Blumer KJ. J Biol Chem 1999;274:34253–34259. [PubMed: 10567399]
37. Skiba NP, Yang CS, Huang T, Bae H, Hamm HE. J Biol Chem 1999;274:8770–8778. [PubMed: 10085118]
38. DeLano, W. L. (2002), DeLano Scientific, San Carlos, CA, USA
Acknowledgements

We thank Chris Fischer for excellent technical assistance. RSM would like to acknowledge Laura A. Tehan, Robyn Pyskadlo and members of the Siena College Spring 2003 Molecular Biology class for contributions to this work. JJGT would also like to acknowledge the UT Austin College of Natural Sciences support for the Center for Structural Biology.
Figure 1.

(A) Model of the G\(_{\alpha_q}\)-GRK2 RH domain complex and their interacting surfaces. The model of G\(_{\alpha_q}\) was homology modeled based on the AlF\(_4^-\) bound structure of G\(_{\alpha_i}\) in complex with RGS4 (11) and then docked with the RH domain as described in Experimental Procedures. The switch regions and the \(\alpha A\) helix of G\(_{\alpha_q}\) (purple and yellow) are labeled, as are the \(\alpha 5\) and \(\alpha 6\) helices of the GRK2 RH domain. These structural elements constitute the principal interaction surfaces of each protein. The proposed plane of the plasma membrane runs along the top of the complex, as shown in the figure. The switch regions of G\(_{\alpha_q}\) are delineated by V182 to Y192 (switch I), V204- T224 (switch II), and D236-R247 (switch III).

(B) Model of G\(_{\alpha_q}\) in complex with RGS4, based on the atomic structure of G\(_{\alpha_i}\)-RGS4 (11). The RH domains of GRK2 and RGS4 both interact with the switch regions of the G protein, but the surface of the RH domain used in the contact is unique. In the RGS4 complex, the \(\alpha 5\) helix faces out of the page, while in the G\(_{\alpha_q}\)-GRK2 complex it forms the principal contact surface. Panels (C) and (D) represent views of G\(_{\alpha_q}\) and GRK2, respectively, as if the complex shown in panel (A) were opened like a book. (C) The GRK2-interacting surface of G\(_{\alpha_q}\). The residues shown as
ball-and-stick models with green carbons are those mutated and analyzed in this study. Thick circles indicate residues that had a dramatic effect upon mutation (as per Table 1), thin circles indicate an “intermediate” effect, and no circles indicate no effect, at least upon GRK2 binding and inhibition of IP$_3$ release. The residues listed in orange are those that each G$_{q}$ residue is predicted to contact. The black sphere represents Mg$^{2+}$. (D) The G$_{q}$-interacting surface of the GRK2 RH domain. The residues shown as ball-and-stick models with green carbons are those mutated and analyzed in this (L118 and E130) and our previous study (22). Thick circles indicate residues that had a dramatic effect upon mutation, thin circles indicate an “intermediate” effect, and no circles indicate no effect, at least upon G$_{q}$ binding. The residues listed in purple are those that each GRK2 residue is predicted to contact. All panels were created using PyMOL (38). The coordinates of the model of the G$_{q}$-GRK2 RH domain complex are available in a pdb file as Supplementary Data.
Figure 2.
Interaction of GST-GRK2-(45–178) with Gαq point mutants activated by AlF4⁻, the Q209L or the R183C mutation. (A) HEK-293 cells were transfected with EE tagged versions of Gαq point mutants and Gβ and Gγ constructs. Cells were lysed and binding to GST-GRK2-(45–178) in the presence (+) or the absence (−) of AlF4⁻ was determined as described in Experimental Procedures. The (+) and (−) lanes represent 40% of the Gαq or Gαq mutant pulled down from the 125 μl of lysate. In these experiments we detect little to no binding of GST-GRK2-(45–178) to Gαq or Gαq point mutants in the absence of AlF4⁻. Underneath the representative western blot the percent of each Gαq mutant pulled down by GST-GRK2-(45–178) in the presence of AlF4⁻ is compared to the control, which is the percent of Gαq pulled.
down by GST-GRK2 (45–178) in the presence of AlF$_4^-$, and is represented graphically as the percent of control + S.D. (B) HEK-293 cells were transfected with EE tagged versions of $\text{G}_{\alpha_q}$Q209L point mutants and $\text{G}\beta$ and $\text{G}\gamma$ constructs. Cells were lysed and binding of the QL mutants to GST-GRK2-(45–178) was determined as described in Experimental Procedures. Results are plotted as described in A. (C) HEK-293 cells were transfected with EE tagged versions of $\text{G}_{\alpha_q}$R183C point mutants and $\text{G}\beta$ and $\text{G}\gamma$ constructs. Cells were lysed and binding of the RC mutants to GST-GRK2-(45–178) was determined as described in Experimental Procedures. The lanes labeled “P” represent 40% of the $\text{G}_{\alpha_q}$ or $\text{G}\alpha_q$ mutant that was present in the pulldown from 200 µl of lysate. The lanes in A, B and C labeled “L” represent 4% of total $\text{G}_{\alpha_q}$ or $\text{G}\alpha_q$ mutant available in the lysate for pull-down. Results are plotted as described in A. The (•) indicates that the amount of the marked $\text{G}_{\alpha_q}$ mutant pulled-down is significantly different (p < 0.05) by one-way ANOVA followed by a Dunnett post-test, than the amount of $\text{G}\alpha_q$ pulled-down by GST-GRK2. The (••) indicates that statistical analysis could not be performed on the binding of GST-GRK2-RH to the K77A-QL, P185K-QL or P185K-RC mutants because there was no detectable pull-down. The data are averages from three to six independent experiments.
Figure 3.
Effect of the Q152A point mutation in G\(_\text{q}\)-RC on the ability of GRK2 to inhibit inositol phosphate production. (A) HEK-293 cells were transfected with 0.1 μg of the constitutively active G\(_{\text{q}}\)-R183C or G\(_{\text{q}}\)-Q152A-RC and 0.2 μg of myc, His-tagged G\(_{\beta}\) and 0.1 μg of G\(_{\gamma}\) and increasing amounts of GRK2-K220R and empty vector up to a total of 1.0 μg of DNA. 24 hrs after transfection the cells were labeled with 2 μCi/ml myo-[\(^{3}\)H]inositol and 16 hours later inositol phosphate production was determined, as described in Experimental Procedures. The results shown are averages from five independent experiments each done in triplicate and displayed as percent control ± S.D. The control is the inositol phosphate production stimulated by G\(_{\text{q}}\)-R183C or G\(_{\text{q}}\)-Q152A-RC in the absence of any co-expressed GRK2-K220R. A (\(\ast\)) denotes a statistically significant difference (p < 0.05) by two-way ANOVA followed by a Bonferroni post-test, between the indicated G\(_{\text{q}}\)-Q152A-RC bar and the G\(_{\text{q}}\)-RC bar transfected with the same amount of GRK2-K220R. A (#) indicates a statistically significant difference (p < 0.05) by one-way ANOVA followed by a Dunnett post-test, between the indicated bar and the control, either G\(_{\text{q}}\)-RC or G\(_{\text{q}}\)-Q152A-RC in the absence of cotransfected GRK2-K220R. (B) Western blots of total cellular lysates from a representative inositol phosphate experiment from (A) probed with the EE monoclonal antibody showing that increasing GRK2-K220R expression does not effect expression of G\(_{\text{q}}\)-R183C or G\(_{\text{q}}\)-Q152A-RC. The bottom panel of Figure 4 B shows the level of GRK2- K220R overexpression. The bands corresponding to 10, 25 and 100 ng of GRK2-K220R transfected can be seen after very short exposures; however, the GRK2 band corresponding to 5 ng of cDNA transfected is barely
visible, even after long exposures, suggesting that comparatively low levels of GRK2 expression can significantly inhibit G\(_{\alpha_q}\) signaling.
Figure 4.
Interaction of GST-RGS2 with Goq point mutants activated by AlF₄⁻, the Q209L or the R183C mutation. (A) HEK-293 cells were transfected with EE tagged versions of Goq point mutants and Gβ and Gγ constructs. Cells were lysed and binding to GST-RGS2 in the presence (+) or the absence (−) of AlF₄⁻ was determined as described in Experimental Procedures. The (+) and (−) lanes represent 40% of the Goq mutant pulled down from the 125 μl of lysate. In these experiments we detect little to no binding of GST-RGS2 to Goq point mutants in the absence of AlF₄⁻. Underneath the representative western blot the percent of each Goq mutant pulled down by GST-RGS2 in the presence of AlF₄⁻ is compared to the control, which is the percent of Goq pulled down by GST-RGS2 in the presence of AlF₄⁻, and is represented.
graphically as the percent of control ± S.D. (B) HEK-293 cells were transfected with EE tagged versions of $G_\alpha_q$-Q209L point mutants and $G_\beta$ and $G_\gamma$ constructs. Cells were lysed and binding of the QL mutants to GST-RGS2 was determined as described in Experimental Procedures. Results are plotted as described in A. (C) HEK-293 cells were transfected with EE tagged versions of $G_\alpha_q$-R183C point mutants and $G_\beta$ and $G_\gamma$ constructs. Cells were lysed and binding of the RC mutants to GST-RGS2 was determined as described in Experimental Procedures. 

The lanes labeled “P” in B and C represent 40% of the $G_\alpha_q$ or $G_\alpha_q$ mutant that was present in the pull-down from 200 $\mu$l of lysate. The lanes in A, B and C labeled “L” represent 4% of total $G_\alpha_q$ or $G_\alpha_q$ mutant available in the lysate for pull-down. Results are plotted as described in A. The (⋆) indicates that the amount of the marked $G_\alpha_q$ mutant pulled-down is significantly different (p < 0.05) by one-way ANOVA followed by a Dunnett post-test, than the amount of $G_\alpha_q$ pulled-down by GST-RGS2. The (⋆⋆) indicates that statistical analysis could not be performed on the binding of GST-RGS2 to the K77A-QL, P185K-QL, P185K-RC, T187K or T187K-QL mutants because there was no detectable pull-down. The data are averages from three to six independent experiments.
Figure 5.
RGS2 inhibition of inositol phosphate production stimulated by G\(\alpha_q\)-RC and G\(\alpha_q\)-RC mutants. (A) HEK-293 cells were transfected with 0.1 \(\mu\)g of the constitutively active G\(\alpha_q\)-R183C, G\(\alpha_q\)-Q81A/RC, G\(\alpha_q\)-R92A/RC, G\(\alpha_q\)-Q152A/RC, or G\(\alpha_q\)-RC/T187K and 0.2 \(\mu\)g of myc, His-tagged G\(\beta\) and 0.1 \(\mu\)g of G\(\gamma\) and increasing amounts of RGS2 and empty vector up to a total of 1.0 \(\mu\)g of DNA. 24 hrs after transfection the cells were labeled with 2 \(\mu\)Ci/ml myo-[\(^{3}\)H]inositol and 16 hours later inositol phosphate production was determined, as described in Experimental Procedures. The results shown are averages from three independent experiments each done in triplicate and displayed as percent control ± SD. The control is the inositol phosphate production stimulated by each mutant in the absence of any co-expressed RGS2. The statistical significance of the difference between the indicated bar and G\(\alpha_q\)-R183C, in the absence of any additional mutations, transfected with equal amounts of RGS2 is denoted by ⋆ (p < 0.05) by one-way ANOVA followed by a Dunnett post-test. A (#) indicates a statistically significant difference (p < 0.05) by one-way ANOVA followed by a Dunnett post-test, between the indicated bar and the control, either G\(\alpha_q\)-RC or a G\(\alpha_q\)-RC mutant in the absence of cotransfected RGS2. (B) Western blots of total cellular lysates from a representative inositol phosphate experiment from (A) probed with the EE monoclonal antibody showing that increasing RGS2 expression does not effect expression of G\(\alpha_q\)-RC or any of the mutants. We
were not able to detect the level of RGS2 overexpression in these experiments; however the decrease in inositol phosphate production suggests that RGS2 expression was increased.
Figure 6. Further mapping of the $\alpha_{q/11}$ binding site on the GRK2 RH domain. **Upper Panel.** Glutathione-agarose beads bearing GST fusion proteins, either WT GSTGRK2-(45–178) or GST-GRK2-(45–178) substituted as indicated, were incubated with bovine brain extract (as a source of $\alpha_{q/11}$) in the presence (+) or absence (−) of aluminum fluoride (AlF$_4^−$). Bound $\alpha_{q/11}$ was visualized by immunoblotting. **Lower Panel.** Fusion proteins used in the GST-pull-down assay above were separated by SDS-PAGE and visualized by Coomassie staining.
Table 1

**Effect of Gαq Point Mutants on RH domain binding.** The table summarizes the effects of the Gαq point mutants on binding to GRK2, RGS4 and RGS2. Pull-down assays were performed with GST-GRK2-(45–178), GST-RGS4 or GST-RGS2 on cell lysates that had been transfected with Gαq containing the different point mutations, as described in Experimental Procedures. There is no detectable binding of Gαq or Gαq mutants to GST alone. Binding to AlF4−-activated forms of the mutants and to mutants in the Gαq-RC background was assessed for GRK2, RGS4 and RGS2; however, RGS4 does not bind to Gαq-QL so the effects of the point mutants in the QL form on binding could only be tested with GRK2 and RGS2. (+++) indicates that similar amounts (81–100% of control as described in Experimental Procedures) of the Gαq point mutant and wt Gαq bound to GRK2, RGS4 or RGS2, (++) indicates 51–80% of control, (+) indicates 21–50% of control and (−) indicates 0–20% of control. ND- not determined. Data are from 2 to 6 experiments.

| Gαq construct | GST-GRK2-(45–178) | GST-RGS2 | GST-RGS4 |
|---------------|-------------------|----------|----------|
|               | AlF4− | QL | RC | AlF4− | QL | RC | AlF4− | RC |
| wt-Gαq        | +++   | +++ | +++ | +++   | +++ | +++ | +++   | +  |
| K77A2         | +++   | −   | +++ | +++   | −   | +++ | +++   | +  |
| K77P          | −      | +++ | ND  | ND     | ND  | ND  | ND     | −   |
| L78D          | ++     | +++ | ND  | ND     | ND  | ND  | ND     | −   |
| Q81A2         | ++     | ++  | ND  | ++     | ++  | ND  | ++     | −   |
| R92A2         | +++    | +   | ND  | ND     | ND  | ND  | ND     | −   |
| V118A         | +++    | +   | ND  | ND     | ND  | ND  | ND     | −   |
| Q152A2        | +      | +   | +   | ND     | ND  | ND  | ND     | −   |
| V184D2        | ++     | +++ | ND  | ND     | ND  | ND  | ND     | −   |
| P185K2        | −      | −   | −   | ND     | ND  | ND  | ND     | −   |
| T187K2        | +++    | +++ | ND  | ND     | ND  | ND  | ND     | −   |
| V240A         | ++     | ++  | ND  | +      | +   | +   | +      | −   |
| D243A         | −      | +++ | ND  | ND     | ND  | ND  | ND     | −   |

1 Mutants are expressed at levels similar to Gαq-wt, Gαq-Q209L or Gαq- R183C, respectively, with the following exceptions: K77A-QL (39% of Gαq-QL), P185K (59% of Gαq), P185K-QL (72% of Gαq-QL), P185K-RC (30% of Gαq-RC) and Q152A-RC (75% of Gαq-RC).

2 The statistical significance of the difference between the indicated mutants and control is indicated in Figures 2 and 4 for GRK2 and RGS2, respectively.

3 For mutants indicated by a (−), statistical analysis could not be performed because there generally was no observable pull-down.

4 Binding of Gαq-L78D to GSTGRK2-RH is significantly different than binding of Gαq to GST-GRK2-RH (p < 0.001) and binding of Gαq-Q81A-RC and Gαq-T187K-RC to GST-RGS4 is statistically different than binding of Gαq-RC to GST-RGS4 (p < 0.001).